Report warns Turkey's pharma boom is restricted by government reimbursement

29 May 2014

Turkey is a key destination for foreign investment, with big pharma increasingly looking at facilities within the country, according to a Pharma Insights report on the country from CPhI Worldwide.

The report, to be presented at CPhI Istanbul next week, includes analysis of the Turkish pharma market conducted amongst all major Turkish manufacturers, evaluating conditions for both foreign and domestic companies.

Chris Kilbee, group director pharma, said the report points towards an increasingly prosperous and innovative marketplace. He said: “Growth domestically and as key regional hub for pharma products supply has firmly put Turkey on the global pharma map. What we are now seeing is an evolution of the industry internally with bold investments being made in biologics and even R&D programs.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK